• Mashup Score: 1
    CAST regimen for acute GVHD prophylaxis after HSCT - 10 month(s) ago

    Al-Homsi AS, Cirrone F, Wo S, et al. PTCy, Abatacept, and Short Course of Tacrolimus for GVHD Prevention Following Haploidentical Transplantation. Blood Advances. 2023; (doi: 10.1182/bloodadvances.2023010545). A Phase Ib-II clinical trial found that a regimen of combined post-transplant cyclophosphamide (PTCy), abatacept, and short-course tacrolimus (CAST) reduced the rate of grades II-IV acute…

    Source: ASTCT Nucleus
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      A Phase Ib-II clinical trial found a regimen of combined post-transplant cyclophosphamide (PTCy), abatacept & short-course tacrolimus reduced the rate of grades II-IV acute #GVHD safely & effectively following haploidentical #HSCT. Read more on Nucleus: https://t.co/Fm1XnZj9X1 https://t.co/drMtla2fd2

  • Mashup Score: 1
    Benefits of HSCT for Patients With AML With MRD After Initial Therapy - 11 month(s) ago

    At the 2023 Great Debates & Updates in Hematologic Malignancies meeting in New York, New York, Andrew Artz, MD, participated in a debate about the benefits of hematopoietic stem cell transplantation among patients with AML with MRD after initial therapy.

    Source: HMP Global Learning Network
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLearnNetwork
      OncLearnNetwork

      In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies #GDUHem meeting, Andrew Artz, MD, highlighted the benefits of #HSCT among patients with #AML with #MRD after initial therapy. Learn more: https://t.co/bYy1IL5tcT… @GreatDebatesCME @cityofhope https://t.co/SwwPTzf7ga

  • Mashup Score: 0
    Considering MRD Before HSCT for Patients With Acute Myeloid Leukemia - 12 month(s) ago

    At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, Richard Stone, MD, debated the role of measurable residual disease when considering hematopoietic stem cell transplantation for patients with acute myeloid leukemia.

    Source: HMP Global Learning Network
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLearnNetwork
      OncLearnNetwork

      In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies #GDUHem meeting, Richard Stone, MD, discussed the role of #MRD when considering #HSCT for patients with #AML. Follow along as he shares his insights! https://t.co/tEPPqkhfge… @GreatDebatesCME @DanaFarber https://t.co/vYp7HN2MgQ

  • Mashup Score: 2
    Donor lymphocytes engineered with SA-FasL to avoid aGVHD - 12 month(s) ago

    Shrestha P, Turan A, Batra L, et al. Engineering Donor Lymphocytes with Fas Ligand Protein Effectively Prevents Acute Graft-Versus-Host Disease. Blood Advances. 2023; (doi: 10.1182/bloodadvances.2022008495).   The key to avoiding acute graft-versus-host disease (aGVHD) after hematopoietic stem cell transplantation is in the design of the donor T cells, researchers report. If engineered to…

    Source: ASTCT Nucleus
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      Researchers find that the design of the donor T cells is key to avoiding acute #GVHD after #HSCT. Engineering SA-FasL protein in these cells may be an approach for prevention. Read more on Nucleus: https://t.co/4zDnmWvmaS https://t.co/HMymkNP9G3

Load More